To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1
Phase 1
- Conditions
- Amphetamine-Related Disorders
- Registration Number
- NCT00100074
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Brief Summary
To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.
- Detailed Description
The primary objective of this study is to characterize the pharmacokinetics of three ascending doses of lobeline in normal volunteers.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
- Healthy individuals with a body mass index between 18 and 30.
- Willing and able to give written consent.
- Must have a negative drug test
- Females must have a negative pregnancy test prior to study drug administration
- Must have no medical contraindications as determined by routine testing
Exclusion Criteria
- Please contact the site for more information
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
U of CA, San Francisco
🇺🇸San Francisco, California, United States